CSRT.L Regulatory News (CSRT)

27 Jul 2006 07:03

Bespak PLC27 July 2006 Bespak plc Executive Appointment Bespak plc, a leader in devices for inhaled drug delivery and anaesthesia, todayannounces the appointment of Jonathan M. Glenn as Group Finance Director,effective 11 September 2006. Jon, aged 37, replaces Martin Hopcroft, who stepsdown from the Board today and will be leaving the Company on 8 September topursue other opportunities. From 1998 to 2005 Jon Glenn was Global Head of Finance of Celltech Group plc.Following the sale of Celltech to UCB, in March 2005 he became Chief FinancialOfficer of Akubio, a Cambridge-based, private equity owned, developer ofinstrumentation for the life sciences industry. At Akubio Jon's responsibilitieshave included Finance, Investor Relations, IT and Legal. He is a member of theInstitute of Chartered Accountants in England and Wales. Jon Glenn has advised that, in accordance with paragraph 9.6.13 (2) - (6) of the Listing Rules, he has no details to disclose. Martin Hopcroft has been Group Finance Director of Bespak since November 2002.He was, previously, Chief Financial Officer of Kvaerner Oil & Gas and GroupFinance Director of Darby Group plc. On 12 July Bespak announced record financial results in the 52 weeks ended 29April 2006. Sales grew 17% and operating profit increased 24%. John Robinson, Bespak Chairman, said: "I would like to thank Martin for his manycontributions to Bespak over the past four years, during which time we haverelied on his technical skills, commitment and good judgement." "Over the last year, Bespak has been transformed to focus on inhaled drugdelivery and anaesthesia with significant opportunities for future growth inboth the US and Europe. I am delighted that someone with Jon's ability isjoining the Board at such an exciting time in Bespak's development. Hisexperience and track record will be a great asset to the company". For further information, please contact: Bespak plc Tel: +44 (0) 1908 525240Mark Throdahl - Chief Executive Maitland Tel: +44 (0) 20 7379 5151Brian HudspithElizabeth Morley About Bespak plc Bespak, a leader in devices for inhaled drug delivery and anaesthesia, developsdelivery systems for the pharmaceutical industry and disposable airwaymanagement products for critical care settings. Bespak's product range includesmetered dose and dry powder inhalers, actuators, inflation valves, breathingcircuits, disposable face masks and laryngeal tubes. The group, which hasfacilities in King's Lynn and Milton Keynes in the UK and Indianapolis, Indianaand Kent, Ohio, in the US, is quoted on the Official List of the London StockExchange (LSE: BPK). For more information, please visit www.bespak.com. This information is provided by RNS The company news service from the London Stock Exchange